Could CBD help curb alcohol cravings? new trial investigates

NCT ID NCT06845124

Recruiting now Disease control Sponsor: Central Institute of Mental Health, Mannheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding cannabidiol (CBD) to standard naltrexone treatment can reduce alcohol cravings in people with alcohol addiction. 150 participants will receive either a high or low dose of CBD plus naltrexone, or a placebo plus naltrexone, for 14 days. The study measures changes in craving scores and tracks outcomes for up to 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cannabidiol (CBD) plus naltrexone
What this could lead to: If successful, this could lead to a new treatment option that reduces alcohol cravings and helps prevent relapse in people with alcohol addiction.
What could go wrong: This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. The treatment is short-term (14 days), and long-term effects or benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL ADDICTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse alcohol dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL ADDICTION ALCOHOLISM

Contacts and locations

Locations

Central Institute of Mental Health
RECRUITING

Mannheim, 68159, Germany
Psychiatric Centre North Baden (PZN)
NOT_YET_RECRUITING

Wiesloch, Baden-Wurttemberg, 69168, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.